The
right
assay.
Done
right.
Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities.
We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.
Our services
Our partners
anteris medical
Anteris medical supports the pharmaceutical, biotech and medical device industries globally by managing the development of combination products, medical devices or in vitro diagnostics. Our broad competencies cover compliance, regulatory affairs combined with innovative, resource-efficient solutions for compliant development and technical documentation as well as marketing and sales expertise.
BioAscent
BioAscent operates the former Merck Sharpe and Dohme automated compound management and logistics facility in Scotland, UK. The company offers state-of-the-art compound collection management services, sample formatting, and worldwide compound shipping and logistics. Through www.compoundcloud.com, BioAscent provides rapid online access to chemical collections, offering a completely customizable ex-pharma compound collection in ready to screen formats.
Metrion Biosciences
Metrion Biosciences is an ion channel focused CRO offering integrated drug discovery services, CiPA compliant cardiac safety profiling, phenotypic assays, translational assays and custom screening services on a fee-for-service or collaboration basis. Metrion’s know-how and breadth of services adds value to drug discovery programs by developing and de-risking ion channel modulators as they progress towards nomination for clinical development.
News
Meet us at the BIO International Convention 2018 in Boston
Assay.Works will be joining the BIO 2018, June 4-7, 2018 in Boston, USA. Meet Dr. Ralf Schwandner, Assay.Works owner and CEO, at booth #1401-5 in the German Pavilion or pre-arrange a personal meeting using the BIO partnering tools.
Assay.Works doubles size of its small molecule screening library
Through a cooperation with BioAscent Discovery Ltd., Assay.Works clients can now access two additional collections of 26k and 50k quality compounds, which complement our existing library of 74k “lead-like” substances.
Assay.Works announces collaboration agreement with Metrion Biosciences.
Combining our high-throughput expertise with Metrion's extensive ion channel know-how and electrophysiology based assays, we now can offer a broad spectrum of services to accelerate our client's ion-channel drug discovery programs.
About Us
Assay.Works builds on the legacy of the HTS Center of a leading biopharmaceutical company where we provided assay, screening, and quantitative biology services for drug discovery programs across therapeutic areas with high medical need. During our 16-year tenure, we developed and implemented more than 250 screens spanning all major drug target classes, and generated over 100,000,000 data sets.
Dr. Ralf Schwandner
Founder and CEO
Biologist and seasoned Lead Discovery specialist with 18 years of experience in the biopharmaceutical industry. Prior to founding Assay.Works, he served as head of Amgen‘s HTS center of excellence at Regensburg, Germany (Amgen Research GmbH).
Dr. Johannes Knop
Founder and COO
Biochemist with 16 years of industry experience in Lead Discovery. Most recently, he was head of Research Operations at Amgen Research GmbH, where he managed Sample Management, cell-based Lead Profiling, Cell Production, Informatics, and EH&S.
Contact Us
please enable javascript to view
Assay.Works GmbH
Am BioPark 11
93053 Regensburg
Germany
T +49 941 2000 1240
F +49 941 2000 1241
please enable javascript to view
www.assay.works